AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00996060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 0
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort.
Study NCT03941977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous introduction of cannula
Description: An 8 gauge cannula is introduced at the site of the bone marrow lesion. The introduction of the cannula is guided by fluoroscopy.
Study NCT03941977 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: MRI scans will be performed on a 1.5 T (Signa Excite HD, GE Healthcare, Waukesha, WI, USA) and a specific knee coil (HD TRKnee 8 Ch High Resolution Knee Array) will be used.
Study NCT03941977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Grafting
Description: A bone substitute consisting of calcium phosphate will be injected through the cannula, previously inserted, filling the area of the bone marrow lesion. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.
Study NCT01754389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT01754389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT01754389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT01754389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT01754389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT01754389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study NCT03070301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 200 mg daily
Study NCT03070301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus 5 mg daily or 2.5mg daily
Study NCT00006229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00006229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Study NCT00006229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00006229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Study NCT00006229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebimastat
Study NCT03223129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Graded intravenous glucose infusion
Description: Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
Study NCT03011164 — intervention group
Intervention type: PROCEDURE
Intervention: Walk and Run
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
Study NCT03169231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenously delivered
Study NCT03608397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
Study NCT00996060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 1
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort.
Study NCT00996060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 2
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day.
Study NCT00996060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 3
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day.
Study NCT00996060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 4
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day.
Study NCT00996060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 5
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day.
Study NCT03045341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB medication (Naltrexone Bupropion combination)
Description: NB medication
Study NCT03608397 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
Study NCT01160159 — intervention group
Intervention type: OTHER
Intervention: Tests
Description: Arterial parameters
Study NCT01160159 — intervention group
Intervention type: OTHER
Intervention: Healthy volunteers
Description: Arterial parameters and blood test
Study NCT03734432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IGAR-Breast TeleOp
Description: Upon consent, each participant will undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while the radiologist operates the system from a remote site.
Study NCT01444690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimiracetam
Description: Capsules for oral administration twice daily
Study NCT01444690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dimiracetam 25 mg
Description: Inactive dose level in capsules administered orally twice daily
Study NCT01747109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREOXYFLOW
Description: Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction
Study NCT01747109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD FACE MASK
Description: Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)
Study NCT00658632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
Study NCT00658632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
Study NCT02412540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Lifestyle Intervention
Description: Dietary, behavioral and activity interventions designed to reduce weight.
Study NCT02976363 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy breast cancer
Study NCT02976363 — intervention group
Intervention type: OTHER
Intervention: Evaluation Maximal Respiratory Pressures
Study NCT04615611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: inhalation of salbutamol
Study NCT02860702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Milk Derived Fortifier
Description: Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
Study NCT02860702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human/Bovine Milk
Description: Bovine milk derived fortification
Study NCT04128956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
Study NCT03983642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wii balance board
Description: Numerous video games exist to interact with the Wii Balance Board. One game that has been used in prior balance studies is Wii Fit.~On the first 4 weeks, balance training started with Soccer Heading game. The participants were asked to control their avatar by leaning to left or to the right in order to avoid the objects that were thrown towards them, and try to score the balls inside the net. The participants performed 3 sets of 5 rounds (2min each), totaling 30 min, and rested for 1 min between each set.~Table Tilt game continued for the remaining 4 weeks. Participants tried to enter balls into the holes by shifting their body weight on the balance board causing it to tilt in all directions. This game was divided into multiple levels of 30 seconds each, repeated over 30 min, with a one-minute rest interval between every 10 minutes of training. Moreover, 20 extra seconds were added each time a participant has won a level.
Study NCT03045341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) counseling
Description: BWL counseling
Study NCT03045341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03045341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02654938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobilan (M-VM3)
Description: Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
Study NCT02654938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% infusion solution of dextrose
Study NCT00141115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: Levetiracetam 1500 mg BID
Study NCT03259815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: P.I.O.S.
Description: Physiologically-Guided Incremental Optimisation Strategy
Study NCT03259815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pre and post-PCI coronary physiology measurements
Description: Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
Study NCT03259815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre and post-PCI coronary physiology measurements
Description: Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
Study NCT01416480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theobromine 300mg
Description: Capsule, b.i.d.
Study NCT01416480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodropropizine 10mg
Description: Syrup, t.i.d.
Study NCT01567995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasone Butyrate 0.05% Cream
Description: Clobetasone Butyrate 0.05% Cream
Study NCT01567995 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle (base cream)
Description: Vehicle (base cream)
Study NCT04588181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy (CBT)
Description: Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
Study NCT04588181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy (CBT)
Description: Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
Study NCT01600092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™ experimental formulation
Study NCT04615611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of placebo
Study NCT00151320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, CHOP, Rituximab
Description: Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4
Study NCT02490722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Four times two hours group based patient education
Study NCT01555268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trebananib
Description: Given IV
Study NCT03022916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nail Polish + Efinaconazole Solution
Description: Application of Jublia to the nail of one big toe on top of the nail polish
Study NCT03022916 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nail polish
Description: Application of nail polish only to both big toe nails
Study NCT03022916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Base Coat + Nail Polish + Top Coat + Efinaconazole Solution
Description: Application of Jublia to the nail of one big toe on top of the nail polish with layers of top coat and base coat
Study NCT03022916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nail Polish + Top Coat + Efinaconazole Solution
Description: Application of Jublia to the nail of one big toe on top of the nail polish with layer of top coat
Study NCT02368314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Enoxaparine
Description: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
Study NCT02368314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Enoxaparine
Description: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
Study NCT01562938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01562938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-557
Description: MEDI-557 low-dose
Study NCT01562938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-557
Description: MEDI-557 high-dose
Study NCT03631316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Valganciclovir
Description: 900 mg daily during 4 days
Study NCT03631316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Innovative Valganciclovir
Description: 900 mg daily during 4 days
Study NCT03482973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Group
Description: 20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).
Study NCT03482973 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20cc placebo (0.9% NaCl) will be administered on each side at two different time points (immediately post operatively and on day 1).
Study NCT01720225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
Study NCT01720225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
Study NCT03605082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0107
Description: * Pharmaceutical form: solution for infusion~* Route of administration: intravenous use
Study NCT03605082 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: solution for infusion~* Route of administration: intravenous use
Study NCT00788541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 6 mg/mL
Description: Administered as an injection into an anterior juxtascleral depot
Study NCT04031625 — intervention group
Intervention type: OTHER
Intervention: Metastatic Colorectal Cancer Database
Description: Metastatic Colorectal Cancer Database
Study NCT02671747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Over Matter; Healthy Bowels, Healthy Bladder
Description: 3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
Study NCT02685735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
Study NCT00788541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 3.75 mg/mL
Description: Administered as an injection into an anterior juxtascleral depot
Study NCT02685735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
Study NCT00986050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
Study NCT00986050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare metal stent prokinetic, chrono, skylor or bluemedical
Description: bare metal stent in culprit artery in acute myocardial infarction
Study NCT00986050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting stent (sirolimus eluting) - CYPHER stent
Description: stent implantation in culprit artery in acute myocardial infarction
Study NCT00788541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 96 mg/mL
Description: Administered as an injection into an anterior juxtascleral depot
Study NCT01555268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given SC
Study NCT01795417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF XP200
Description: Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device
Study NCT01795417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XP200 RF device
Description: 4 RF treatments of periorbital region on one side of the face
Study NCT01555268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00378144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine/Paracetamol
Description: Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime \[Paracetamol (500 mg) and Pseudoephedrine (30 mg)\]
Study NCT03226535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-CT Fusion
Description: The Clear Guide SCENERGY is an Ultrasound-CT fusion device which supplements existing ultrasound and CT capabilities. The participants randomly selected (out of 20 patients) for use of the Clear Guide SCENERGY (test group) will receive ultrasound-CT fusion guidance from the MDs performing the procedure.
Study NCT02309307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Repair Device (VergenixTM STR)
Description: Administration of Soft Tissue Repair Device